Advances in antifibrotic therapy.
Advances in antifibrotic therapy.
复制标题
DOI：
10.1586/17474124.2.6.803
复制
发表时间：
2008-12
影响因子：
3.9
通讯作者：
Friedman SL
中科院分区：
文献类型：
--
作者：
Ghiassi-Nejad Z;Friedman SL
在定义肝纤维化的分子病理生理学方面的持续进展为开发抗纤维化治疗提供了一个全面的框架。事实上，将新药推向临床的最大限制是临床试验和治疗终点缺乏明确性，而不是缺乏有前途的药物。一系列治疗方法，包括为其他适应症开发的治疗方法，以及专门为肝纤维化开发的治疗方法，正在接近或处于临床试验中。大多数集中于攻击肝损伤和/或活化的星状细胞和肌成纤维细胞的特征，它们是细胞外基质或瘢痕蛋白的主要来源。因此，损伤和星状细胞活化的特征为这些新兴药物的分类提供了有用的模板，并为纤维化肝病患者提供了一类新的治疗方法。
Sustained progress in defining the molecular pathophysiology of hepatic fibrosis has led to a comprehensive framework for developing anti-fibrotic therapies. Indeed, the single greatest limitation in bringing new drugs to the clinical setting is lack of clarity about clinical trial and treatment endpoints, not the lack of promising agents. A range of treatments, including those developed for other indications, as well as those specifically developed for hepatic fibrosis, are nearing or in clinical trials. Most are focused on attacking features of either hepatic injury and/or activated stellate cells and myofibroblasts, which are the primary sources of extracellular matrix, or scar proteins. Thus, features of injury and stellate cell activation provides a useful template for classifying these emerging agents, and point to a new class of therapies for patients with fibrosing liver disease.